Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.

ABSTRACT:

Background and aims

The pharmacokinetics (PK) and single-dose tolerability of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist being developed for once-weekly treatment of type 2 diabetes (T2D), weight management, and nonalcoholic steatohepatitis, was evaluated in subjects with renal impairment versus healthy subjects with normal renal function.

Methods

Forty-five subjects, categorized by baseline renal status, i.e. mild (n = 8, estimated glomerular filtration rate [eGFR] 60-89 mL/min/1.73m²), moderate (n = 8, eGFR 30-59 mL/min/1.73m²), severe renal impairment (n = 7, eGFR < 30 mL/min/1.73m²), end-stage renal disease requiring dialysis (n = 8), and normal renal function (n = 14, eGF

SUBMITTER: Urva S 

PROVIDER: S-EPMC8332596 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature